FDA accepts Supplemental NDA for Cabozantinib for Patients with Advanced Neuroendocrine Tumors August 13, 2024
505(b)(2) NDA for Lutetium Lu 177 Dotatate Injection submitted to the FDA for the treatment of somatostatin receptor-positive GEP-NETS July 17, 2024
FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) February 26, 2024
Radiomedix and Orano Med Initiate Ph 2 Multi-Center Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers February 26, 2024
Merck to Acquire Harpoon Therapeutics, including HPN328 in certain patients with small cell lung cancer and neuroendocrine tumors January 10, 2024
23ME-00610 Ph 1/2a trial in advanced neuroendocrine and ovarian cancer patient cohorts expanded January 10, 2024
U.S. FDA Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung December 4, 2023
Lutathera® demonstrated statistically significant and clinically meaningful PFS in first line advanced GEP-NETs October 3, 2023
Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Announced September 6, 2023
Promising Top-Line Results from Ph 2 Trial of BXCL701 in small cell neuroendocrine metastatic castration-resistant prostate cancer (SCNC) patients announced January 17, 2023
